The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Major Depressive Disorder (MDD) Market Research Report 2025
Synopsis
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
The global Major Depressive Disorder (MDD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
This report aims to provide a comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Major Depressive Disorder (MDD).
Report Scope
The Major Depressive Disorder (MDD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Major Depressive Disorder (MDD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Major Depressive Disorder (MDD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck
Bristol-Myers Squibb
Segment by Type
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Major Depressive Disorder (MDD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Major Depressive Disorder (MDD) is a common mental illness characterized by persistent low mood that interferes with the person's ability to eat, work, sleep and other activities. MDD is also referred to as clinical depression or recurrent depression. The common symptoms of this mental disorder are insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. The rising prevalence of major depression has led to a sharp increase in the patient volume suffering from depression. Currently, many treatments and therapies are available for major depression but the market still holds a large scope of growth opportunities with high unmet needs of the market.
The global Major Depressive Disorder (MDD) market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The rising geriatric population prone to depression and surging prevalence of anxiety disorders, including phobias and generalized anxiety disorder, are further contributing toward the growing demand for antidepressants to treat mental illnesses over the forecast period. Moreover, the introduction of technologically advanced therapies, such as medical implants used for brain stimulation and virtual reality exposure therapies using smartphone-based applications, furnish patients with innovative treatment alternatives.
This report aims to provide a comprehensive presentation of the global market for Major Depressive Disorder (MDD), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Major Depressive Disorder (MDD).
Report Scope
The Major Depressive Disorder (MDD) market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Major Depressive Disorder (MDD) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Major Depressive Disorder (MDD) companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer
GlaxoSmithKline
Merck
AstraZeneca
Eli Lily
Johnson & Johnson
Forest Laboratories
Sanofi-Aventis
H. Lundbeck
Bristol-Myers Squibb
Segment by Type
Antidepressant Drugs
SSRIs
SNRIs
Benzodiazepines
Others
Segment by Application
Hospitals
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Major Depressive Disorder (MDD) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Major Depressive Disorder (MDD) Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Antidepressant Drugs
1.2.3 SSRIs
1.2.4 SNRIs
1.2.5 Benzodiazepines
1.2.6 Others
1.3 Market by Application
1.3.1 Global Major Depressive Disorder (MDD) Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Major Depressive Disorder (MDD) Market Perspective (2019-2030)
2.2 Major Depressive Disorder (MDD) Growth Trends by Region
2.2.1 Global Major Depressive Disorder (MDD) Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Major Depressive Disorder (MDD) Historic Market Size by Region (2019-2024)
2.2.3 Major Depressive Disorder (MDD) Forecasted Market Size by Region (2025-2030)
2.3 Major Depressive Disorder (MDD) Market Dynamics
2.3.1 Major Depressive Disorder (MDD) Industry Trends
2.3.2 Major Depressive Disorder (MDD) Market Drivers
2.3.3 Major Depressive Disorder (MDD) Market Challenges
2.3.4 Major Depressive Disorder (MDD) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Major Depressive Disorder (MDD) Players by Revenue
3.1.1 Global Top Major Depressive Disorder (MDD) Players by Revenue (2019-2024)
3.1.2 Global Major Depressive Disorder (MDD) Revenue Market Share by Players (2019-2024)
3.2 Global Major Depressive Disorder (MDD) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Major Depressive Disorder (MDD) Revenue
3.4 Global Major Depressive Disorder (MDD) Market Concentration Ratio
3.4.1 Global Major Depressive Disorder (MDD) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Major Depressive Disorder (MDD) Revenue in 2023
3.5 Major Depressive Disorder (MDD) Key Players Head office and Area Served
3.6 Key Players Major Depressive Disorder (MDD) Product Solution and Service
3.7 Date of Enter into Major Depressive Disorder (MDD) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Major Depressive Disorder (MDD) Breakdown Data by Type
4.1 Global Major Depressive Disorder (MDD) Historic Market Size by Type (2019-2024)
4.2 Global Major Depressive Disorder (MDD) Forecasted Market Size by Type (2025-2030)
5 Major Depressive Disorder (MDD) Breakdown Data by Application
5.1 Global Major Depressive Disorder (MDD) Historic Market Size by Application (2019-2024)
5.2 Global Major Depressive Disorder (MDD) Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Major Depressive Disorder (MDD) Market Size (2019-2030)
6.2 North America Major Depressive Disorder (MDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Major Depressive Disorder (MDD) Market Size by Country (2019-2024)
6.4 North America Major Depressive Disorder (MDD) Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Major Depressive Disorder (MDD) Market Size (2019-2030)
7.2 Europe Major Depressive Disorder (MDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Major Depressive Disorder (MDD) Market Size by Country (2019-2024)
7.4 Europe Major Depressive Disorder (MDD) Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Major Depressive Disorder (MDD) Market Size (2019-2030)
8.2 Asia-Pacific Major Depressive Disorder (MDD) Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Major Depressive Disorder (MDD) Market Size by Region (2019-2024)
8.4 Asia-Pacific Major Depressive Disorder (MDD) Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Major Depressive Disorder (MDD) Market Size (2019-2030)
9.2 Latin America Major Depressive Disorder (MDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Major Depressive Disorder (MDD) Market Size by Country (2019-2024)
9.4 Latin America Major Depressive Disorder (MDD) Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Major Depressive Disorder (MDD) Market Size (2019-2030)
10.2 Middle East & Africa Major Depressive Disorder (MDD) Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Major Depressive Disorder (MDD) Market Size by Country (2019-2024)
10.4 Middle East & Africa Major Depressive Disorder (MDD) Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Major Depressive Disorder (MDD) Introduction
11.1.4 Pfizer Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Major Depressive Disorder (MDD) Introduction
11.2.4 GlaxoSmithKline Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Merck
11.3.1 Merck Company Detail
11.3.2 Merck Business Overview
11.3.3 Merck Major Depressive Disorder (MDD) Introduction
11.3.4 Merck Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.3.5 Merck Recent Development
11.4 AstraZeneca
11.4.1 AstraZeneca Company Detail
11.4.2 AstraZeneca Business Overview
11.4.3 AstraZeneca Major Depressive Disorder (MDD) Introduction
11.4.4 AstraZeneca Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.4.5 AstraZeneca Recent Development
11.5 Eli Lily
11.5.1 Eli Lily Company Detail
11.5.2 Eli Lily Business Overview
11.5.3 Eli Lily Major Depressive Disorder (MDD) Introduction
11.5.4 Eli Lily Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.5.5 Eli Lily Recent Development
11.6 Johnson & Johnson
11.6.1 Johnson & Johnson Company Detail
11.6.2 Johnson & Johnson Business Overview
11.6.3 Johnson & Johnson Major Depressive Disorder (MDD) Introduction
11.6.4 Johnson & Johnson Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.6.5 Johnson & Johnson Recent Development
11.7 Forest Laboratories
11.7.1 Forest Laboratories Company Detail
11.7.2 Forest Laboratories Business Overview
11.7.3 Forest Laboratories Major Depressive Disorder (MDD) Introduction
11.7.4 Forest Laboratories Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.7.5 Forest Laboratories Recent Development
11.8 Sanofi-Aventis
11.8.1 Sanofi-Aventis Company Detail
11.8.2 Sanofi-Aventis Business Overview
11.8.3 Sanofi-Aventis Major Depressive Disorder (MDD) Introduction
11.8.4 Sanofi-Aventis Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.8.5 Sanofi-Aventis Recent Development
11.9 H. Lundbeck
11.9.1 H. Lundbeck Company Detail
11.9.2 H. Lundbeck Business Overview
11.9.3 H. Lundbeck Major Depressive Disorder (MDD) Introduction
11.9.4 H. Lundbeck Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.9.5 H. Lundbeck Recent Development
11.10 Bristol-Myers Squibb
11.10.1 Bristol-Myers Squibb Company Detail
11.10.2 Bristol-Myers Squibb Business Overview
11.10.3 Bristol-Myers Squibb Major Depressive Disorder (MDD) Introduction
11.10.4 Bristol-Myers Squibb Revenue in Major Depressive Disorder (MDD) Business (2019-2024)
11.10.5 Bristol-Myers Squibb Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
